The document discusses the benefits of clinical trial authors submitting supplemental materials and making raw trial data publicly available, such as enabling other researchers to verify results, test secondary hypotheses, and aid the design of future trials, while also outlining some arguments against data sharing and proposing a code of conduct for data sharing. It concludes by suggesting medical journals require data availability for publication to help address issues around researchers restricting access to trial data.